10-Q: Harmony Biosciences Reports Strong Q1 2025 Revenue Growth Driven by WAKIX Sales

Harmony Biosciences Holdings, Inc. announces a 19.5% increase in net product revenue for Q1 2025, driven by increased WAKIX sales and a price increase.

Summary

• Harmony Biosciences Holdings, Inc. reported its financial results for the quarter ended March 31, 2025.
• Net product revenue increased by 19.5% to $184.7 million compared to $154.6 million in Q1 2024, driven by a 17% increase in units shipped and a 7% price increase, partially offset by higher rebates.
• Cost of product sales increased by 16.4% to $32.0 million, representing 17.3% of net product revenue.
• Research and development expenses increased by 55.7% to $34.5 million, driven by investments in EPX-100, ZYN002, Pitolisant GR/HD, and personnel costs.
• Sales and marketing expenses increased by 12.8% to $30.7 million, due to increased patient engagement and marketing activities.
• General and administrative expenses increased by 21.7% to $31.2 million, primarily due to legal and professional fees related to patent lawsuits.
• Interest expense decreased by 15.4% to $3.8 million, while interest income increased by 13.9% to $5.0 million.
• Net income for the quarter was $45.6 million, compared to $38.3 million for the same period in 2024.
• The company had cash, cash equivalents, and investments of $610.2 million as of March 31, 2025.
• The company believes its existing cash, cash equivalents, and investments will meet its operational liquidity needs and fund potential investing activities for the next 12 months.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a healthy cash position, and advancement of multiple pipeline programs. While there are risks associated with patent litigation and regulatory approvals, the overall tone is optimistic.

Positives

• Strong revenue growth of 19.5% driven by WAKIX sales.
• Significant cash position of $610.2 million provides financial flexibility.
• Advancement of multiple pipeline programs, including ZYN002, EPX-100, and Pitolisant GR/HD.
• Alignment with the FDA on a path to sNDA resubmission for the pediatric cataplexy indication.
• Initiation of the Phase 3 TEMPO study in patients with PWS.
• EMA granted approval for the marketing authorization of WAKIX for the treatment of narcolepsy with or without cataplexy in children six and older.
• FDA approved the company's sNDA for WAKIX for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.

Negatives

• Increased research and development expenses may impact near-term profitability.
• Ongoing patent litigation with generic manufacturers poses a risk to future revenue.
• FDA did not approve the company's sNDA seeking to expand the WAKIX label for the treatment of pediatric patients with cataplexy.

Risks

• The company faces ongoing patent litigation from generic manufacturers seeking to market generic versions of WAKIX.
• The company's future revenue is dependent on the successful defense of its intellectual property.
• The company's research and development efforts may not result in successfully commercialized products.
• The company depends on a single supplier of the active pharmaceutical ingredient (API) for its commercial product, WAKIX, and single API suppliers for each of its potential product candidates.
• The company may not be able to obtain regulatory approvals for pitolisant for other indications as well as any other product candidates.

Future Outlook

Harmony Biosciences is focused on expanding its pipeline through acquisitions and development of new indications for pitolisant and other product candidates. The company anticipates several key milestones in the near term, including data readouts for ZYN002 and Pitolisant GR, and regulatory submissions for pediatric cataplexy and BP1.15205.

Management Comments

• At Harmony, we are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases.
• We are expanding our pipeline through the acquisition of additional assets that focus on addressing the unmet needs of patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs.
• We are targeting assets that will allow us to further leverage the expertise and infrastructure that we have successfully built at Harmony so we can optimize the benefit of internal synergies.

Industry Context

Harmony Biosciences operates in the competitive pharmaceutical industry, focusing on rare neurological diseases. The company's strategy involves both organic growth through the development of its existing pipeline and inorganic growth through acquisitions of promising assets. The company faces competition from other pharmaceutical companies developing treatments for narcolepsy, PWS, FXS, LGS, and other neurological disorders.

Comparison to Industry Standards

• Harmony Biosciences' revenue growth of 19.5% in Q1 2025 is strong compared to the average growth rate of pharmaceutical companies in the rare disease space.
• The company's cash position of $610.2 million provides a significant advantage compared to smaller biotech companies.
• The company's focus on acquiring and developing assets in rare neurological diseases aligns with the industry trend of targeting niche markets with high unmet needs.
• Competitors in the narcolepsy market include Jazz Pharmaceuticals (Xyrem, Xywav) and Avadel Pharmaceuticals (Lumryz).
• Companies developing treatments for Fragile X Syndrome include Roche and Novartis.
• Companies developing treatments for Dravet Syndrome and Lennox-Gastaut Syndrome include GW Pharmaceuticals (Epidiolex) and Zogenix (Fintepla).

Legal Proceedings

• Harmony Biosciences is involved in patent litigation with multiple generic manufacturers seeking to market generic versions of WAKIX.
• On October 31, 2024, the Company reached an agreement with Novugen Pharma to resolve the dispute over Novugen's ANDA for a generic pitolisant hydrochloride product.
• On March 24, 2025, the Company reached an agreement with Annora to resolve the dispute over Annora's ANDA for a generic pitolisant hydrochloride product.

Related Party Transactions

• Harmony Biosciences has a right-of-use agreement with Paragon Biosciences, LLC, for office space in Chicago, Illinois.
• The company incurred $73 for each of the three months ended March 31, 2025, and 2024, in expenses to Paragon, which are included in general and administrative in the unaudited condensed consolidated statements of operations and comprehensive loss.

Stakeholder Impact

• Shareholders: The strong financial performance and pipeline progress are positive for shareholders.
• Employees: The company's growth and expansion provide opportunities for employees.
• Patients: The company's focus on developing new treatments for rare neurological diseases benefits patients with unmet needs.
• Suppliers: The company's increased sales and research and development activities may lead to increased demand for suppliers.
• Creditors: The company's strong financial position reduces the risk for creditors.

Next Steps

• Resubmit sNDA for pediatric cataplexy in the second quarter of 2025.
• Receive topline data readout for the Pitolisant GR pivotal bioequivalence study in the third quarter of 2025.
• File an investigational medicinal product dossier (IMPD) with the EMA in mid-2025 and begin first-in-human studies in the second half of 2025 for BP1.15205.
• Receive topline data for the ZYN002 Phase 3 registrational trial in the third quarter of 2025.
• Initiate a Phase 3 registrational study in 2025 in 22q deletion syndrome, pending positive data from the REFCONNECT study.

Key Dates

Keywords

WAKIX, pitolisant, narcolepsy, revenue, clinical trials, FDA, Harmony Biosciences, ZYN002, EPX-100, research and development